expectations, page-23

Onshow - will be definitely interesting to see how people try and value some of the large signings when they occur

The reason being is the different sectors that these large deals could come from.

PART 1 :

One of the exciting areas is the recent left field development of the Microtitre plate market which I believe with the proven cost savings could yield in excess of $20m pa

PART 2 :

Point of Care : A deal with a major like Philips or Alere would see potential 3-5 % royalty on hundreds of millions in sales per annum on tests like Troponin and PSA - $20m +

PART 3 : Major IVD company - anywhere from $10 - $30m pa

PART 4 : A deal with Life Technologies - they supply over 50% of the global IVD market with beads

If a certain combination of these deals a PE in excess of 20 would be plausible as these contracts would be huge and ramp up to full production Would give investor confidence of large revenues for 10 years plus

Probably some DCF valuations on free cash flow would create more than a little interest :)